A speculative development that has tapped into West Cambridge’s expanding life science cluster is under agreement to a California investor for $332.5 million.

HCP Inc. said it’s agreed to acquire 35 CambridgePark Drive, the 224,000-square-foot office and lab building known as the Alewife Research Center, for nearly $1,485 per square foot from The Davis Cos. and Invesco.

The building is 100 percent leased to Syros Pharmaceuticals, Ribon Therapeutics, Codiak, Glympse Bio and Eisai Inc. The transaction is expected to close in December, HCP Inc. said in a press release.

Irvine, California-based HCP has acquired more than 1.3 million square feet of life science space in Greater Boston in the past two years, including 35 CambridgePark Drive and a development site at 101 CambridgePark Drive.

“Class A life science real estate continues to experience unprecedented demand and the cluster strategy we have employed, combined with our mix of stabilized and development properties, will allow our tenants to grow within our portfolio,” Scott Brinker, HCP’s chief investment officer, said in a statement.